1. Home
  2. ATEX vs IOVA Comparison

ATEX vs IOVA Comparison

Compare ATEX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anterix Inc.

ATEX

Anterix Inc.

HOLD

Current Price

$107.14

Market Cap

2.0B

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$4.40

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATEX
IOVA
Founded
1997
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
ATEX
IOVA
Price
$107.14
$4.40
Analyst Decision
Buy
Buy
Analyst Count
1
10
Target Price
$50.00
$9.00
AVG Volume (30 Days)
331.9K
15.6M
Earning Date
02-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
891.80
14.84
EPS
4.83
N/A
Revenue
$6,501,000.00
N/A
Revenue This Year
$2.70
$47.74
Revenue Next Year
$10.04
$40.31
P/E Ratio
$19.80
N/A
Revenue Growth
7.79
N/A
52 Week Low
$17.58
$1.76
52 Week High
$113.00
$5.64

Technical Indicators

Market Signals
Indicator
ATEX
IOVA
Relative Strength Index (RSI) 55.98 48.44
Support Level $91.00 $3.77
Resistance Level $112.45 $4.45
Average True Range (ATR) 6.81 0.38
MACD -1.47 -0.09
Stochastic Oscillator 50.22 27.98

Price Performance

Historical Comparison
ATEX
IOVA

About ATEX Anterix Inc.

Anterix Inc is the holder of licensed 900 MHz spectrum (896-901/935-940 MHz) with coverage spanning the contiguous United States, Hawaii, Alaska, and Puerto Rico. The Company is focused on commercializing its spectrum assets and delivering intelligent infrastructure solutions, including private broadband networks, tower access, and turnkey connectivity management, to utility and critical infrastructure enterprises. It provides mission-critical private 900 MHz spectrum to the utility sector and integrated deployment solutions that support a secure, resilient, and decarbonized future. Its solutions include 900 MHz Private Wireless, TowerX, and CatalyX.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: